| Date Checked | 2026-02-19 22:13:34 |
|---|---|
| Graham Number | (PB)nan vs (PE)70.90 |
| Over / Under Value Percentage | 0.00% vs nan% |
| Dividend Yield | 3.04% |
| Dividend Date | 2026-02-17 |
| Symbol | ABBV |
| AssetType | Common Stock |
| Name | AbbVie Inc |
| Description | AbbVie Inc is a prominent American biopharmaceutical firm, founded in 2013 as a spin-off from Abbott Laboratories, dedicated to the research, development, and commercialization of cutting-edge therapies across immunology, oncology, virology, and neuroscience. Renowned for its flagship immunology product, Humira, AbbVie is actively expanding its portfolio through strategic acquisitions and partnerships, enhancing its ability to tackle some of the most pressing global health challenges. With a strong commitment to innovation and a robust development pipeline, AbbVie is well-positioned to maintain its leadership in the biopharmaceutical sector and deliver substantial value to institutional investors. |
| CIK | 1551152 |
| Exchange | NYSE |
| Currency | USD |
| Country | USA |
| Sector | HEALTHCARE |
| Industry | DRUG MANUFACTURERS - GENERAL |
| Address | 1 NORTH WAUKEGAN ROAD, NORTH CHICAGO, IL, UNITED STATES, 60064-6400 |
| OfficialSite | https://www.abbvie.com |
| FiscalYearEnd | December |
| LatestQuarter | 2025-12-31 |
| MarketCapitalization | 394886709000 |
| EBITDA | 29416665000 |
| PERatio | 94.27 |
| PEGRatio | 0.381 |
| BookValue | -1.495 |
| DividendPerShare | 6.65 |
| EPS | 2.37 |
| RevenuePerShareTTM | 34.49 |
| ProfitMargin | 0.0691 |
| OperatingMarginTTM | 0.35 |
| ReturnOnAssetsTTM | 0.0959 |
| ReturnOnEquityTTM | 0.111 |
| RevenueTTM | 61160002000 |
| GrossProfitTTM | 43818000000 |
| DilutedEPSTTM | 2.37 |
| QuarterlyEarningsGrowthYOY | -0.887 |
| QuarterlyRevenueGrowthYOY | 0.1 |
| AnalystTargetPrice | 245.33 |
| AnalystRatingStrongBuy | 6 |
| AnalystRatingBuy | 13 |
| AnalystRatingHold | 9 |
| AnalystRatingSell | 0 |
| AnalystRatingStrongSell | 1 |
| TrailingPE | 94.27 |
| ForwardPE | 15.72 |
| PriceToSalesRatioTTM | 6.46 |
| PriceToBookRatio | 50.46 |
| EVToRevenue | 7.49 |
| EVToEBITDA | 30.38 |
| Beta | 0.334 |
| 52WeekHigh | 241.12 |
| 52WeekLow | 159.05 |
| 50DayMovingAverage | 224.02 |
| 200DayMovingAverage | 209.64 |
| SharesOutstanding | 1767385000 |
| SharesFloat | 1763921000 |
| PercentInsiders | 0.104 |
| PercentInstitutions | 75.245 |
| ExDividendDate | 2026-01-16 |
| naga | 1 |
| etoro | 1 |
| dateChecked | 2026-02-19 22:13:34 |
| fresh | 1 |